Naturally Produced Cannabinoids for Neuroprotection From Concussion
Key facts
- Who runs it
- University of Regina
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 1 Jun 2026
- Expected to end
- Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Broad spectrum cannabinoid formulation
- Placebo gel capsule
- Record updated
- 21 July 2026
Who can take part
- Age
- 19 years to 35 years
- Sex
- Men only
- Healthy volunteers
- Can take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Healthy male adults between 19-35 years of age that compete in contact sport athletics
- Participants with no known cerebrovascular or cardiovascular complications
- Participants will not be habitual recreational users of cannabis (i.e., <1 day/week) or tobacco users
- Participants that agree not use any other cannabis or tobacco products while enrolled in the study
- Participants willing to provide a list of any prescription medications they are taking
- Ability to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, perceptual-cognitive, and functional motor skills laboratory tests
- Participants who are capable of giving signed informed consent
Who cannot take part
- Use of cannabis-based therapy within 2 months (participants who have previously used a cannabis based therapy may be included if they have a 2-month period without use of cannabis-based therapy prior to enrollment in the study)
- Participants who are taking prescription medications such as psychotropic medications with serotonergic activity, including Selective Serotonin Reuptake Inhibitors (i.e. Fluoxetine), Tricyclic Antidepressants (i.e. Elavil, Nortriptyline) and Atypical Neuroleptics (i.e. Risperidone, Seroquel)
- Initiation or dosage change of oral or injected steroids within 3 months
- Participants that are being medically supervised for anxiety, depression, Post Traumatic Stress Disorder (PTSD), mood disorder, psychotic disorders or any cerebrovascular and cardiovascular complications
- Allergy or known intolerance to any of the compounds within the study preparation
- Inability of study participants to attend assessments on a regular basis at the pre-determined times, or failure to take the drug daily
- Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator)
- Unable to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, and functional motor skills laboratory tests
- Female
- Must not travel to the USA during study period; USA laws do not permit cross border with cannabis products
- Participants with any level of cannabis in their blood samples when sampled at the commencement of the study will be excluded
- If they already have a concussion at the time of starting the study
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
This trial is currently available in Canada.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this double-blind, placebo-controlled, cross over study is to learn about the neuroprotective properties of a broad-spectrum cannabinoid formulation in normal healthy adults engaged in elite contact sport competition.
Read full original descriptionShow less
The main question it aims to answer :
• Is the broad-spectrum cannabinoid formulation neuroprotective for athletes participating in competitive contact sports? Can this formulation facilitate recovery in those who suffer from concussion by reducing inflammation and/or reduce the number of concussions sustained without adverse physiological and psychological dysfunction when administered daily?
Participants will:
* be given a broad-spectrum cannabinoid gel capsule or a placebo twice daily. * have blood samples taken to analyze pharmacokinetics and pharmacodynamics of cannabinoid metabolites, liver function, complete blood count and blood differential, inflammatory biomarkers and genetic analysis * have stool samples collected for gut microbiome analysis; * undergo testing sessions, which will include psychological and health questionnaires, equipment to record signals from the brain and heart, and safety laboratory tests.
The 2 groups in the trial
- Broad sprectrum cannabinoid gel capsuleTreatment being tested
Gel capsule containing broad spectrum cannabinoid formulation
Treatment: Broad spectrum cannabinoid formulation
- PlaceboPlacebo, for comparison
Placebo gel capsule
Treatment: Placebo gel capsule
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Naturally Produced Cannabinoids for Pain Management and Neuroprotection From Concussion During Participation in Contact Sports: Neuroprotection
- Criteria questions
- Built from NCT07715864, who can take part
- Record updated
- 21 July 2026